In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Irati de GoñiCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.ORCID 0009-0007-5300-9251 Aizpea Artetxe-ZurutuzaCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.
Joseba ElizazuCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-6859-0970 Raul Garcia-Garcia de GarayoCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.
Jhonatan Vergara-ArceCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.ORCID 0009-0007-4796-6952 Mikel AzkargortaProteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCIII, 48160 Derio, Spain.
Mireia Toledano-PinedoLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), 28006 Madrid, Spain.
Alicia Porro-PérezLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), 28006 Madrid, Spain.ORCID 0000-0002-8310-1549 Felix ElortzaProteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCIII, 48160 Derio, Spain.ORCID 0000-0001-8839-5438 Jose Luis Marco-ContellesLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), 28006 Madrid, Spain.
Nicolas SampronCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.
Nerea Iturrioz-RodriguezCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.
Ander MatheuCellular Oncology Group, Biogipuzkoa (Biodonostia) Health Research Institute, 20014 San Sebastian, Spain.
Funding
Basque Government PRE_2020_1_0130Instituto de Salud Carlos III CD22/00076Instituto de Salud Carlos III DTS24/00153Instituto de Salud Carlos III FORT23-00026Instituto de Salud Carlos III PI19/01355Instituto de Salud Carlos III PI22/01905
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
glioblastomaglioma stem cellsHDAC inhibitionMSMproliferation
Identifiers
PMID41471109
PMCPMC12736535
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390